期刊文献+

银杏达莫联合依达拉奉治疗急性脑梗死的临床效果分析 被引量:5

下载PDF
导出
摘要 目的探讨银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效。方法将90例急性脑梗死患者随机分成两组,对照组给予依达拉奉治疗,观察组在对照组的基础上给予银杏达莫注射液联合治疗,观察2周后两组的临床疗效和神经功能恢复情况。结果观察组的有效率为93.3%,对照组的有效率为77.1%,两者比较有统计学差异(P<0.05)。治疗组的神经功能缺损评分在治疗后比治疗前有所下降,且差异有统计学意义。结论依达拉奉联合银杏达莫治疗急性脑梗死具有确切的临床疗效,可有效提高治愈率,恢复神经功能,改善预后,值得推广。
作者 张发梅
出处 《中国医学工程》 2011年第6期90-90,93,共2页 China Medical Engineering
  • 相关文献

参考文献4

二级参考文献12

  • 1顾学兰,丁新生,狄晴,赵忠新,陈家慧,李健华.依达拉奉注射液治疗急性脑梗死的临床疗效评价[J].中国新药与临床杂志,2005,24(2):113-116. 被引量:172
  • 2彭小祥,胡小红,邓小容,邱峥.晴尔对颈内动脉系统TIA患者的血流动力学及血液流变学的影响[J].海南医学,2004,15(12):53-53. 被引量:1
  • 3田方起,李斌,苏兰,张玉香.依达拉奉治疗急性期脑梗死者的有效性分析[J].海南医学,2005,16(2):104-104. 被引量:13
  • 4脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-383. 被引量:15727
  • 5Forbes CD. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thromb Res, 1998,92:S1-6.
  • 6International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet,1997,349:1569-1581.
  • 7CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Collaborative Group, CAST(Chinese Acute Stroke Trial). Lancet, 1997, 349: 1641-1649.
  • 8Paul SF, Karyn M, Cynthia DL. The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacology,1996, 50:131-139.
  • 9Pierr S, Jamme I, Robert K, et al. Ginkgo biloba extract(EGb 761) protects Na,K-ATPase isoenzymes during cerebral ischemia. Cell Mol Biol,2002,48:671-679.
  • 10Barber PA, Auer RN, Buchan AM, et al. Understanding and managing ischemic stroke. Can J Physiol Pharmacol, 2001, 79:283-296.

共引文献77

同被引文献42

  • 1各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33020
  • 2马小董,詹佩娟,徐金华.依达拉奉联合银杏达莫治疗急性脑梗死的临床观察[J].中国中西医结合急救杂志,2007,14(1):60-60. 被引量:10
  • 3陈丽 张太珍 李敏莉.银杏达莫注射液治疗急性脑梗塞疗效观察.健康必读(中旬刊),2011,:213-214.
  • 4顾莹辉 王利刚 张春良.神经节苷脂联合银杏达莫注射液治疗脑梗死疗效观察.中国美容医学,2011,:379-379.
  • 5Felberg RA, Burgin WS, Grotta JC. Neuroprotection and the is chemic cascade,CNS Spectrums,2(100,5(3)..52 58.
  • 6Nakamura T, Kuioda Y, Yamashita S, et al. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intrac- erehral hemorrhage. Stroke, 2008,39 (2) : 463 469.
  • 7Tanaka M. Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent. Nihon Yakurigaku Zasshi,2002,119(5):301-308.
  • 8Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Con trol Clin Trials, 1996,17 ( 1 ) : 1-12.
  • 9Edaraven Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone(MC1 186 ),on aeute brain infrac- tion. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis, 2003,15 (3) : 222-229.
  • 10Peters O, Back T, Lindauer U, et a l. Increased formation of reac tive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood FloW Metab, 1998,18(2) : 196-205.

引证文献5

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部